Latest Regulatory Filings News

Antares Metals Limited reported a net cash outflow of $704,000 for the December 2024 quarter, driven by operating expenses, while maintaining a healthy cash balance of nearly $3 million.

Winsome Resources has taken a significant step forward in developing its Adina Lithium Project by submitting the Preliminary Information Statement to Quebec authorities, initiating a structured permitting process and enhancing stakeholder engagement.

Multistack International Limited reported a net cash outflow from operating activities of $72,916 for the December 2024 quarter but ended with robust cash reserves of $975,608. Despite ongoing negative cash flows, the company remains confident in sustaining operations through secured financing and strategic asset acquisitions.

Amcor plc has taken a pivotal step in its proposed merger with Berry Global by filing the definitive joint proxy statement with the SEC, setting the stage for shareholder votes in February. Integration planning is well underway as both companies prepare to unite their packaging expertise.

Respiri Limited reports a standout December quarter marked by a 67% surge in patient program enrolments and robust revenue growth, bolstered by strategic acquisition synergies from Orb Health. The company is poised for further expansion in 2025 amid promising contract negotiations and evolving US healthcare reimbursement policies.

Galilee Energy reports a $1.9 million R&D tax refund and terminates its merger with Vintage Energy, while maintaining steady progress at its Glenaras Gas Project and a robust cash position of $4.38 million.

Brazilian Critical Minerals Limited reported a net cash outflow from operating activities in the December 2024 quarter but maintains a solid cash position supported by significant unused financing facilities.

Raptis Group Limited reported a positive net cash inflow from operating activities of $54,509 for the quarter ended December 31, 2024, ending with $303,102 in cash and equivalents. The company recorded no investing or financing cash flows during the period.

Memphasys Limited marks a pivotal quarter with the completion of clinical trials for its Felix™ System, strategic market expansions in Greater China and the Middle East, and a successful capital raise to fuel growth.

InhalerX Limited reported a negative cash flow for the December quarter despite securing a substantial $38.5 million funding facility aimed at advancing its clinical trials. The company has yet to draw on this facility, maintaining a cautious cash position as it progresses its drug development programs.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.

Vonex Limited reported a net cash inflow of $779,000 from operating activities in Q4 2024, maintaining a solid cash position despite accelerated debt repayments following a change of control.